Andrew K. Balo

Andrew K. Balo filed 145 disclosures between March 10, 2016 and October 7, 2025, nearly all at Dexcom Inc (141), a Nasdaq company, plus four at GlucoTrack, Inc. (as Director). At Dexcom the filings do not spell out a role.

This is a seller's record: 102 sales worth EUR 33,738,589, with a median of EUR 199,078, and no purchase. The largest, EUR 3,643,035, dates from June 20, 2016; next come March 11, 2020 (EUR 1,838,881) and September 15, 2020 (EUR 1,763,255). The record also counts 11 share grants, 9 option exercises and 23 filings of another kind.

Activity sits mostly between 2016 and 2021, at 18 to 29 filings a year, with a maximum of 29 in 2021. It then drops to 4 in 2022, 3 in 2023 and 4 in 2025. 102, 89 and 80 trades by Balo fall within 30 days of colleagues at Dexcom Inc, in that order. All on the same side. Names in order: Steven Robert Pacelli, Kevin R. Sayer and Patrick Michael Murphy.